| For: | Isakov V. Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass. World J Gastroenterol 2025; 31(20): 105346 [PMID: 40495947 DOI: 10.3748/wjg.v31.i20.105346] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i20/105346.htm |
| Number | Citing Articles |
| 1 |
Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou. Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery. Expert Opinion on Drug Discovery 2025; 20(12) doi: 10.1080/17460441.2025.2579124
|
| 2 |
Maria-Zinaida Dobre, Bogdana Virgolici, Daciana Costina Andrada Dunca-Stefan, Ioana-Cristina Doicin, Iulia-Ioana Stanescu-Spinu. Inflammation—Insulin Resistance Crosstalk and the Central Role of Myokines. International Journal of Molecular Sciences 2025; 27(1) doi: 10.3390/ijms27010060
|
| 3 |
Mengyan Zhao, Tao Guo, Chaoyang Liu. Exploring the impact of childhood obesity on sarcopenia-related traits: A 2-way Mendelian randomization analysis. Medicine 2026; 105(8) doi: 10.1097/MD.0000000000044812
|
| 4 |
Jie Li, Jiang Li, Xiaoqin Xu, Ningjian Wang, Bin Wang, Yingli Lu. Frailty, cardiovascular health, and the risk of mortality and extrahepatic diseases in patients with metabolic dysfunction-associated steatotic liver disease. Maturitas 2026; 208 doi: 10.1016/j.maturitas.2026.108917
|
| 5 |
Ashwin Krishnamoorthy, Vaynika Gupta. Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: A critical review of diagnostic, mechanistic, and therapeutic intersections. World Journal of Gastroenterology 2025; 31(31): 110481 doi: 10.3748/wjg.v31.i31.110481
|
| 6 |
Shinya Sato, Hiroaki Takaya, Tadashi Namisaki, Tatsuya Nakatani, Jun-ichi Hanatani, Yuki Tsuji, Koh Kitagawa, Norihisa Nishimura, Kosuke Kaji, Hitoshi Yoshiji. Diabetes as a Risk Factor for Sarcopenia in Patients with MASH-Related Cirrhosis. Journal of Clinical Medicine 2025; 14(24) doi: 10.3390/jcm14248691
|
| 7 |
Masafumi Oyama, Tadashi Namisaki, Akihiko Shibamoto, Satoshi Iwai, Masayoshi Takami, Yuki Tsuji, Yukihisa Fujinaga, Hiroaki Takaya, Takashi Inoue, Norihisa Nishimura, Shinya Sato, Koh Kitagawa, Kosuke Kaji, Akira Mitoro, Kiyoshi Asada, Hiroyuki Masuda, Junichi Hanatani, Hitoshi Yoshiji. Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLD. International Journal of Molecular Sciences 2025; 26(19) doi: 10.3390/ijms26199560
|
| 8 |
André J. Scheen. GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations. Diabetes & Metabolism 2026; 52(1) doi: 10.1016/j.diabet.2025.101708
|
| 9 |
Yazhao Sun, Xiao Yu, Tianhao Zhang, Chunlan Bai, Lingxiao Zhang, Ya Ma. Association of triglyceride-glucose muscle loss index with major adverse cardiovascular events in angina patients: the potential mediating role of inflammation. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1813601
|
| 10 |
Hami Hemati, Madison B. Blanton, Lauren Rutt, Nicholas Keiran, Rebecca Geron, Florence Lima, Rebecca L. McCullough, Ilhem Messaoudi. Alcohol consumption exacerbates high-fat diet-mediated disruptions in myelopoiesis and osteoclastogenesis in mouse models of metabolic dysfunction-associated liver diseases. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1783132
|
| 11 |
Keyan Gao, Liwen Xun, Shalei Hao, Min An, Lingfeng Zuo, Jiayu Wang, Ying Wang, Junhua He. MASLD and sarcopenia research (2012–2025): a multi-database bibliometric analysis. Frontiers in Nutrition 2026; 13 doi: 10.3389/fnut.2026.1834112
|
| 12 |
Julia M. Boster, Melanie G. Cree, Megan M. Kelsey, Kristen J. Nadeau, Alexander Chaidez, Zhaoxing Pan, Shikha S. Sundaram. Relative Skeletal Muscle Mass Is Associated With Hepatic Steatosis in Adolescents With Overweight and Obesity. Pediatric Obesity 2026; 21(4) doi: 10.1111/ijpo.70108
|
| 13 |
Almir Fajkić, Yun Wah Lam, Rijad Jahić, Ivan Ćavar, Antonio Markotić, Andrej Belančić. From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis. Current Issues in Molecular Biology 2026; 48(2) doi: 10.3390/cimb48020178
|
| 14 |
Marion Pradeau, Julie-Catherine Coll, Ana Berteaux, Véronique Paquet, Isabelle Robillard Frayne, Stéphanie Ferland, Matthieu Ruiz, Anne-Marie Carreau. Metabolomic and lipidomic plasma profiles according to metabolic dysfunction-associated steatotic liver diseases (MASLD) stages in the absence of type 2 diabetes (T2D).. Metabolomics 2026; 22(3) doi: 10.1007/s11306-026-02437-1
|
| 15 |
Carlo Acierno, Fannia Barletta, Alfredo Caturano, Riccardo Nevola, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Luca Rinaldi. Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights. Nutrients 2025; 17(13) doi: 10.3390/nu17132229
|
| 16 |
Kamila Magomedzhamilievna Kurbanova, Karina Vladimirovna Yakovleva, Suvanet Fazilovna Magaramova, Dayana Anzorovna Khabekirova, Fidan Talib Kizi Mastalieva, Karina Viktorovna Lokhmatova, Alina Andreevna Goloveshko, Alina Manvelovna Grigoryan, Natalia Aleksandrovna Lysenko, Shakira Hasmagomedovna Yunusova. Non-Alcoholic Fatty Liver Disease in Outpatient Practice of Southern Russia: A Multicenter Study of 480 Patients. Journal of Biochemical Technology 2025; 16(4) doi: 10.51847/nkoLUMv4Im
|